To study the effects of augmenting central dopamine activity on deficit state symptoms, we have proposed a sixteen week, double-blind, placebo- controlled trial of selegiline for patients on a stable dose of neuroleptics. It is hoped that selegiline, a selective MAO-B inhibitor that increases the amount of dopamine, will alleviate negative symptoms without concurrently exacerbating the positive symptoms and side-effects associated with typical non-selective MAO-inhibitors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Intramural Research (Z01)
Project #
1Z01MH002595-02
Application #
3781473
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
United States
Zip Code